Maze Therapeutics (NASDAQ:MAZE) CEO Sells $621,683.25 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 23,865 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $26.05, for a total transaction of $621,683.25. Following the sale, the chief executive officer directly owned 319,079 shares of the company’s stock, valued at approximately $8,312,007.95. This trade represents a 6.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Trading Up 0.7%

NASDAQ MAZE traded up $0.19 during mid-day trading on Wednesday, hitting $26.60. The company’s stock had a trading volume of 657,539 shares, compared to its average volume of 688,291. The firm has a market capitalization of $1.47 billion, a P/E ratio of -10.51 and a beta of 2.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. Maze Therapeutics, Inc. has a 52-week low of $9.83 and a 52-week high of $53.65. The stock’s fifty day simple moving average is $25.67 and its two-hundred day simple moving average is $36.25.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. Research analysts expect that Maze Therapeutics, Inc. will post -2.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 31st. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a report on Wednesday, March 11th. Guggenheim boosted their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. BTIG Research restated a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $66.00.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Maze Therapeutics during the first quarter valued at about $57,000. Goldman Sachs Group Inc. purchased a new stake in shares of Maze Therapeutics during the first quarter worth about $145,000. Rhumbline Advisers acquired a new position in shares of Maze Therapeutics in the first quarter worth about $80,000. Geode Capital Management LLC lifted its stake in shares of Maze Therapeutics by 8.8% in the second quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after acquiring an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after purchasing an additional 3,371 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.